Inovio Pharmaceuticals Inc (NASDAQ:INO) has been given an average rating of “Buy” by the eight brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $6.69.
INO has been the topic of several research analyst reports. Maxim Group reissued a “buy” rating and issued a $6.00 price target on shares of Inovio Pharmaceuticals in a report on Sunday, August 11th. Citigroup reissued a “buy” rating and issued a $4.00 price target (down from $7.00) on shares of Inovio Pharmaceuticals in a report on Monday, September 16th. Piper Jaffray Companies lowered their price target on shares of Inovio Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, July 17th. ValuEngine raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, September 18th.
A number of institutional investors have recently added to or reduced their stakes in the business. Wedbush Securities Inc. bought a new position in shares of Inovio Pharmaceuticals during the third quarter worth approximately $34,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Inovio Pharmaceuticals during the second quarter worth approximately $40,000. Creative Planning bought a new position in shares of Inovio Pharmaceuticals during the second quarter worth approximately $50,000. Stoneridge Investment Partners LLC bought a new position in shares of Inovio Pharmaceuticals during the second quarter worth approximately $50,000. Finally, LPL Financial LLC bought a new position in shares of Inovio Pharmaceuticals during the second quarter worth approximately $61,000. 46.44% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ INO traded down $0.05 on Thursday, reaching $2.52. The company had a trading volume of 700,600 shares, compared to its average volume of 975,813. The company has a debt-to-equity ratio of 1.49, a quick ratio of 4.59 and a current ratio of 4.59. The company’s fifty day moving average is $2.25 and its 200-day moving average is $2.68. The firm has a market capitalization of $250.54 million, a price-to-earnings ratio of -2.40 and a beta of 2.05. Inovio Pharmaceuticals has a 1-year low of $1.91 and a 1-year high of $5.50.
Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.02). The company had revenue of $0.14 million during the quarter, compared to the consensus estimate of $4.69 million. Inovio Pharmaceuticals had a negative net margin of 1,560.70% and a negative return on equity of 142.10%. During the same period in the prior year, the company earned ($0.07) earnings per share. On average, research analysts forecast that Inovio Pharmaceuticals will post -1.06 earnings per share for the current year.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Featured Article: What is the Consumer Price Index (CPI)?
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.